Novartis CEO says FDA's extended approval of breast cancer drug is a 'landmark' for the firm
Vas Narasimhan, CEO of Novartis, comments on the progress of the firm's Kisqali metastatic breast cancer drug after the company recently received an extended approval for it from the U.S. Food and Drug Administration.
FDA expands use of Kisqali to early stage breast cancer patients
Women with early stage breast cancer may now take Kisqali, a medication already approved for advanced disease.
FDA Expands Use of Breast Cancer Drug Kisqali
The FDA approval of Kisqali for this early breast cancer population, including those with NO [hasn't spread to nearby lymph nodes] disease, is a pivotal moment in improving our approach to care,” said Dr.
FDA Expands Approval Of Breast Cancer Drug Kisqali To Earlier-stage Patients
Women with early-stage breast cancer may now take Kisqali, a medication already approved for advanced disease, following the U.S. Food and Drug Administration's expanded approval of the treatment, drug maker Novartis announced Tuesday.
Breast cancer drug Kisqali gets FDA approval to prevent cancer recurrence
The breast cancer drug Kisqali has received FDA approval to reduce cases of cancer recurrence. The drug was found to reduce the chances of a patient's breast cancer coming back by 25%.
FDA expanded their approval on drug cancer drug
First News
Novartis not joining the 'frenzy' of weight loss drugs, CEO says
Swiss pharmaceutical giant Novartis said Wednesday that it does not plan to enter into the "frenzy" of weight loss drugs.
Benzinga on MSN1d
Novartis Skips Weight Loss Drug 'Frenzy,' Focuses on 'Unique Position' for Cancer, Alzheimers, and Parkinsons Treatments
Novartis CEO Vas Narasimhan stated that the company will not compete in the "frenzy" of the weight loss drug market dominated ...
How Novartis plans to thrive without competing directly with Eli Lilly in weight loss drug market
As weight-loss treatments dominate the pharmaceutical market, Swiss drugmaker Novartis AG (SWX: NOVN) is choosing a different ...
pharmaphorum1d
Lilly on alert as new Kisqali approval threatens Verzenio
Verzenio was approved for a similar adjuvant indication last year, having been used for a couple of years only in patients ...
Novartis Steers Clear of Weight Loss Drug “Frenzy”
The CEO of Novartis (NYSE:NVS) said Wednesday that the Swiss pharmaceutical giant does not plan to enter into the “frenzy” of weight loss drugs, preferring instead to focus on areas where it can build ...
Jim Cramer Says It Will Take Time For Novartis AG (NVS) To ‘Get The Attention Of Investors’
We recently compiled a list of the Top 10 Stocks on Jim Cramer’s Radar. In this article, we are going to take a look at where ...
ENDPOINTS NEWS2d
No­var­tis’ Kisqali snags FDA ap­proval to re­duce re­cur­rence in pa­tients with ear­ly forms of breast can­cer
Novartis was already riding a wave of momentum with Kisqali, and now it has a new FDA nod to break into the early breast ...